Lixte Biotechnology Inc. (LIXT)
1.33
0.03 (2.31%)
At close: Mar 03, 2025, 3:58 PM
1.21
-9.02%
After-hours: Mar 03, 2025, 03:59 PM EST
No 1D chart data available
| Bid | 1.16 |
| Market Cap | 3.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.77M |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -0.77 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.42 |
| Volume | 30,220 |
| Avg. Volume (20D) | 68,831 |
| Open | 1.33 |
| Previous Close | 1.30 |
| Day's Range | 1.22 - 1.33 |
| 52-Week Range | 1.22 - 4.40 |
| Beta | -0.04 |
About LIXT
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at var...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2007
Employees 3
Stock Exchange NASDAQ
Ticker Symbol LIXT
Website https://lixte.com
2 weeks ago
-15.35%
Lixte Biotechnology shares are trading lower after...
Unlock content with
Pro Subscription
11 months ago
+55.75%
LIXTE shares are trading higher after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100.
